358 Index Name Paper ref. Name Paper ref. Oreagba, I Wed 144 Orellana, S Tue 326 Orensanz, LM Mon 411 Orer, SH W17.4 Orescanin-Dusic, Z Thu 329, Tue 122, Thu 318 Oriá, RB Tue 255 Orlandi, S FC18.4.5 Orlando, G Mon 105, Wed 434, Wed 329 Orlando, R Wed 404 Orozco, FAJ Thu 330 Orrenius, S FC13.2.3 Orrico, M Mon 275 Orrtiz, E Thu 178 Ørskov, C FC05.3.5 Orta, IA Mon 125 Orta, ML Mon 040 Ortega, JE Thu 031, Thu 399 O'Shea, R Mon 045 Ospina, DA Mon 480 Østergaard, L Wed 240 Østergaard, S Thu 404 Östervall, J FC13.4.5 Östman, J Thu 278 Ostrow, G Wed 417 O'Sullivan, S Wed 285, Tue 460 Oswald, S Tue 049, Tue 041 Oswald, S Tue 045 Ota, M Wed 128 Otake, S Wed 186 Oteo, I Wed 111 Otsu, K FC06.4.3 Otsuguro, K Mon 101 Otsuka, A Mon 035 Ottenheijm, HCJ Wed 085 Otto, M Mon 090 Otto, S FC13.4.5 O'Tuathaigh, C FC17.2.1 Otukesh, H Thu 006 Ouanes, I Thu 346 Ouanes, L Wed 348, Mon 004 Oueslati, N FC11.3.6 Overvad, K Tue 482 Ovesjö, M-L Mon 371 Oyagi, A Thu 406 Oyama, Y Thu 331 Oyamada, H Wed 128 Özatýk, Y Wed 420 Ozawa, H Thu 403 Özcan, G Thu 049 Ozdemir, O Thu 266, Mon 199, Tue 461, Thu 269 Özdemir, V W16.6 Ozkan, MH Thu 229 Özkutlu, U W05.2 Ozokwere, JJC Thu 332 Oztop, I Tue 411 Öztürk, N Tue 245 Ozturk, EI Thu 230 Ozyogurtcu, H Tue 461 Pacifici, R Mon 375 Pacini, A Tue 446, Mon 391 Packeu, A Thu 426 Padin, F Tue 116 Padrosa, A Tue 133 Pageaux, GP FC04.2.6, Mon 141 Pai, H-C Mon 326 Paillard, F Mon 145, Mon 132 Paintaud, G Tue 198, Tue 190 Painter, A W06.3 Pairoj, V Tue 127 Pajdo, R Tue 463 Pajeau, P Tue 171 Pajor, L Wed 284 Pajouhesh, H FC03.2.1 Pakarinen, P Mon 215 Pal, A FC16.2.6 Pala Kara, Z Tue 245 Palatini, P Wed 404 Palea, S Tue 205, Tue 206, Tue 204, Mon 244, Tue 203 Palivoda, M Tue 137 Pallas, M Mon 443 Palma, C Wed 152 Palme, R Wed 397 Palmero, M Mon 138 Mon 477, Mon 472, Mon 481, Thu 407 Palmero, MM Mon 473 Palmiere, PCR Tue 101 Palombo, E Wed 360 Pamplona, F Thu 396 Pan, X Tue 299 Pan, Y FC14.1.2, Thu 103, Tue 426 Panagiotidis, G Wed 147 Panagopoulos, P Tue 126 Panahi, Y Thu 005, Thu 311 Panayiotou, C Thu 278 Panchaud, A Mon 022, FC10.5.3 Panda, VS Wed 304 Pandolfo, G Thu 419 Panduriv, M Tue 167 Pang, CCY Mon 184 Panhelainen, AE Thu 194 Pani, L SS01.4 Panich, U Tue 007 Pantovic, S Thu 231, Wed 019 Pantsurkin, VI Tue 179 Panula, P FC14.3.6 Papadimitriou, E Thu 232 Papadopoulos, C Mon 143 Papadopoulou-Daifoti, Z W33.4 Papaioannidou, P Tue 246 Papakosta, M FC03.2.6 Papantonakis, PB Tue 302 Papapetropoulos, A Thu 202 Papapetropoulos, As FC15.3.6 Papaseit, E Thu 178, Mon 109 Papathanasopoulos, P Wed 074 Papouchado, M Mon 280 Papp, GJ Wed 197 Papp, J Mon 100 Papp, JG Wed 284 Paquet, B Wed 443 Parada, C Mon 276 Paraskakis, E Tue 224 Pardo, L W01.1.3 Pardo, R Mon 109, Mon 375, Thu 177, Thu 178 Pardo-Andreu, GL Wed 344
Name Paper ref. Name Paper ref. Paredes, SD Wed 352, Mon 407 Parente, L Tue 406 Pariente, JA Mon 407 Parini, P Tue 387, Tue 383 Park, BK FC13.2.2 Park, HW Tue 046 Park, I-C Tue 427 Park, J Tue 047 Park, K Mon 226, Mon 013, Tue 349, Mon 029, Thu 418, Mon 033 Park, M Mon 427 Parkel, S Thu 077 Parks, V Tue 012 Parlar, A Thu 233 Parmar, S Wed 148 Parsaee, H Tue 424 Parsons, M Mon 086 Pascale, A Mon 152 Pascual, MA Thu 394, Thu 395 Pascual-Brazo, J Wed 401 Pasko, K Mon 347 Paskulin, R Thu 329, Thu 318 Pasqualina, F Thu 400 Passeri, D FC18.4.5 Pastor, A Thu 178 Pastor, M YI.03 Pastor, MJ FC09.2.7 Pastorello, M Tue 127, Thu 254 Pastro, L Wed 231 Pásztor, M Mon 261 Patacchini, R W03.4 Patapoutian, A FC03.1.2 Pataricza, J Wed 197, Wed 284 Patel, K FC16.1.6 Patel, P Wed 149, Thu 113 Paterniti, I FC18.1.5, FC18.3.6, Mon 286 Patil, AW Wed 381 Patil, RN Thu 333 Patiño-Camacho, S Mon 009 Patonay, T Mon 163 Patras, X Mon 108 Patrignani, P FC09.4.2, W18.3, Mon 281, Wed 235 Patrikainen, S Mon 447 Patrono, C W18.1, W18.4 Patte-Reutenauer, J W04.3.2 Patterson, TA Wed 150 Paukkeri, E-L Tue 247 Paul, F Thu 013 Paul, R Thu 224 Paul-Clark, M Thu 241 Paule, MG Wed 150 Paules, RS FC13.4.3 Paulo, M FC15.4.5 Paunescu, H Mon 274 Paunovic, B W02.2.7 Paunovic, G Tue 149 Pavelkova, V Tue 137 Pavlyuchenko, V FC06.1.6 Pawar, V Thu 333 Pawlik, M Tue 463 Pawlik, WW Tue 463 Pawlowska, I Wed 279, Mon 181 Paz Lopes, MT Tue 428 Pazos, A Wed 401, Thu 408 Pechanova, O Mon 148, Mon 293 Pedersen, A FC05.4.6 Pedersen, AF Thu 066 Pedersen, DS FC11.5.1, Tue 248 Pedersen, L FC04.1.6 Pedersen, MFH FC11.5.6 Pedersen, MØ Tue 359, Tue 248 Pedersen, ME Thu 234 Pedersen, RS Wed 151 Pedersen, S FC05.1.1, Thu 026 Pedroso, A Wed 140 Peeters, M FC11.4.6 Peiro, C W08.1, Tue 134 Peitl, B Tue 142, Mon 163, Tue 125 Mon 150, Mon 167, Tue 128 Peixoto, AVB Tue 281 Pekiner, C Wed 438, Mon 155 Pekson, R Thu 334 Pelkonen, O PL16, Thu 348 Pellaquini, EH Mon 289 Pellegrini, M Mon 375 Peltonen, I Mon 444 Peltonen, T Tue 166 Pena Dias, J Thu 073 Peña, C Tue 114 Pendek, R YI.04 Peng, M Mon 331 Peng, SR Wed 291 Peng, X Wed 099 Peng, X-Q Wed 182 Peng, Y Mon 445, Mon 466 Penkowa, M Tue 359 Tue 248 Penninx, BWJH Wed 432, Tue 096 Peoch, K Wed 191 Peoc'h, K FC01.4.4 Pepedil, F Wed 249 Pepper, M Mon 368 Perälä, M Mon 410, Tue 436 Peränen, J Mon 341 Percie du Sert, N Tue 471 Perdan-Pirkmajer, K Mon 074, Tue 048 Perdomo, L Tue 226 Pereira do Vale, AC YI.08 Pereira, F Wed 180 Pereira, FC YI.08, Thu 193 Pereira, J Wed 214 Pereira, JCM W31.3 Pereira, L Wed 394, Tue 123 Pereira, M Wed 394 Pereira, P Thu 187 Pereira, R Tue 241 Pereira, SA Wed 130 Perez Vizcaino, F Thu 235 Pérez, E Tue 087 Pérez, JA Mon 125 Perez, M Thu 177, Thu 178 Pérez, R Wed 152, Wed 217 Pérez, T Tue 016 Perez-Aso, M Thu 050, Wed 068 Perez-Gutthann, S FC04.2.6 Perez-Maña, C FC14.4.5, Thu 178, Thu 177 Index 359
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303:
FC15 Endothelium in health and dise
- Page 304 and 305:
FC16 Natural products: Past and fut
- Page 306 and 307:
FC16 Natural products: Past and fut
- Page 308 and 309:
FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor